

Non-Alcoholic Steatohepatitis (NASH) Market: Key Impacting Factors and Investment Pockets 2021-2030

PORTLAND, OR, UNITED STATES, October 20, 2021 /EINPresswire.com/ -- Non-alcoholic steatohepatitis (NASH), is a common liver disease, often called as silent liver disease. It is asymptomatic until its later stages, and thus many patients are unaware of their condition. NASH is projected to lead the cause of liver transplantation in the U.S. in the coming years. Some major



Non-alcoholic steatohepatitis (NASH), is a common liver disease, often called as silent liver disease. It is asymptomatic until its later stages, and thus many patients are unaware of their condition."

Allied Market Research

factors such as higher prevalence of NASH, expected launch of pipeline drugs, and higher number of unmet needs drive the growth of this market. However, poor diagnosis of NASH due to the lack of ideal diagnostic technologies limit the growth of the NASH market.

Non-Alcoholic Steatohepatitis (NASH) Market, by Drug Type and Sales Channel: Global Opportunity Analysis and Industry Forecast, 2021-2025," the global non-alcoholic steatohepatitis (NASH) market was valued at \$1,179 million in 2017, and is expected to reach \$21,478 million by 2025, growing at a CAGR of 58.4% from 2021 to 2025.

Explore Report Description@ <https://www.alliedmarketresearch.com/nonalcoholic-steatohepatitis-NASH-market>

At present, there is no FDA-approved drug available in the market for the treatment of NASH. Lifestyle interventions are the first-line approach to manage patients with NASH. Based on drug type, the market is segmented into vitamin E & pioglitazone, ocaliva, elafibranor, and selonsertib & cenicriviroc. Vitamin E & pioglitazone segment contributes majorly due to effectiveness in a treatment of steatosis, inflammation, hepatocyte ballooning, and scarring in NASH patients.

Non-alcoholic steatohepatitis (NASH) market is projected to exhibit double digit growth during the forecast period majorly due to growth in demand for ideal NASH therapeutics, surge in the prevalence of NASH, and expected launch of pipeline drugs during the forecast period. In addition, surge in prevalence of diabetes & obesity and improvement in awareness of NASH in developing region is projected to supplement the market growth during the forecast period. However, poor diagnosis of the disease and lack of ideal diagnostic techniques are projected to

limit the market growth.

Based on sales channel, the market is segmented into hospital pharmacy, online provider, and retail pharmacy. At present, the retail pharmacy segment is major revenue generator, and is estimated to show dominance during the forecast period due to the patient convenience and strong presence of retail pharmacies around the world. However, the online provider segment is projected to exhibit the fastest market growth due to rise in awareness of online pharmacies and increase in preference for online purchase of drugs over the traditional methods.

Key Findings of the Non-alcoholic Steatohepatitis (NASH) Market:

North America accounted approximately one half of the global market share in 2017 and is expected to remain dominant throughout the forecast period. Major factors that driving the market growth in North America are, early diagnosis of the disease, higher prevalence of disease, and strong presence of pipeline drugs. On the other hand, Asia-Pacific is expected to experience the highest CAGR of 62.62% during the forecast period primarily due to growth in prevalence of NASH along with the increase in prevalence of diabetes & obesity and rise in awareness of NASH among the patients. Furthermore, growth in number of R&D activities, development in diagnostic technologies, and increase in healthcare spending is expected to drive the NASH market in Asia-Pacific region.

For Purchase Enquiry: <https://www.alliedmarketresearch.com/purchase-enquiry/224>

The key players profiled in the non-alcoholic steatohepatitis (NASH) market report include Allergan plc. (Tobira Therapeutics), Cadila Healthcare Limited, Conatus Pharmaceuticals Inc., Galmed Pharmaceuticals Ltd, Gemphire Therapeutics Inc., Genfit SA, Gilead Sciences, Inc., Intercept Pharmaceuticals, Inc., Novartis International AG, and Shire Plc.

Avenue Basic Plan | Library Access | 1 Year Subscription |

Sign up for Avenue subscription to access more than 12,000+ company profiles and 2,000+ niche industry market research reports at \$699 per month, per seat. For a year, the client needs to purchase minimum 2 seat plan.

Request for 14 days free trial: <https://www.alliedmarketresearch.com/avenue/trial/starter>

“We have also published few syndicated market studies in the similar area that might be of your interest. Below are the report title for your reference, considering Impact of Covid-19 Over This Market which will help you to assess aftereffects of pandemic on short-term and long-term growth trends of this market.”

Trending Reports in Healthcare Industry:

[Hearing Aids Market Global Research By 2030](#)

[Prostate Cancer Market Global Research By 2030](#)

[Ablation Technologies Market Global Research By 2030](#)

About Us:

Allied Market Research (AMR) is a full-service market research and business-consulting wing of Allied Analytics LLP based in Portland, Oregon. Allied Market Research provides global enterprises as well as medium and small businesses with unmatched quality of "Market Research Reports" and "Business Intelligence Solutions." AMR has a targeted view to provide business insights and consulting to assist its clients to make strategic business decisions and achieve sustainable growth in their respective market domain.

Pawan Kumar, the CEO of Allied Market Research, is leading the organization toward providing high-quality data and insights. We are in professional corporate relations with various companies and this helps us in digging out market data that helps us generate accurate research data tables and confirms utmost accuracy in our market forecasting. Each and every data presented in the reports published by us is extracted through primary interviews with top officials from leading companies of domain concerned. Our secondary data procurement methodology includes deep online and offline research and discussion with knowledgeable professionals and analysts

David Correa

Allied Analytics LLP

+18007925285 ext.

[email us here](#)

Visit us on social media:

[Facebook](#)

[Twitter](#)

[LinkedIn](#)

This press release can be viewed online at: <https://www.einpresswire.com/article/554339152>

EIN Presswire's priority is source transparency. We do not allow opaque clients, and our editors try to be careful about weeding out false and misleading content. As a user, if you see something we have missed, please do bring it to our attention. Your help is welcome. EIN Presswire, Everyone's Internet News Presswire™, tries to define some of the boundaries that are reasonable in today's world. Please see our Editorial Guidelines for more information.

© 1995-2021 IPD Group, Inc. All Right Reserved.